Crucial Vote Looms for CureVac Shareholders as BioNTech Acquisition Nears Finish Line

The proposed acquisition of CureVac by BioNTech is accelerating toward its final stages. CureVac investors face a pivotal decision on November 25, when they will cast their votes on the $1.25 billion merger agreement. This critical shareholder meeting approaches as recent financial disclosures from the acquiring company introduce fresh considerations for the deal.

BioNTech presented its third-quarter financial results, reporting substantial revenues of approximately €1.5 billion. Despite this significant income, the company registered a net loss of €28.7 million. Part of this deficit stems from resolving contractual disputes with GSK related to a licensing agreement that originally involved CureVac. This financial entanglement highlights the already complex relationship between the two German biotech firms.

Notably, Read more...